Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Front Pharmacol
Κύριοι συγγραφείς: Ermisch, Michael, Bucsics, Anna, Vella Bonanno, Patricia, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Fürst, Jurij, Garuolienė, Kristina, van der Graaff, Martin, Gulbinovič, Jolanta, Haycox, Alan, Jones, Jan, Joppi, Roberta, Laius, Ott, Langner, Irene, Martin, Antony P., Markovic-Pekovic, Vanda, McCullagh, Laura, Magnusson, Einar, Nilsen, Ellen, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Sauermann, Robert, Schuurman, Ad, Ramos, Ricardo, Vlahovic-Palcevski, Vera, Zara, Corinne, Godman, Brian
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Frontiers Media S.A. 2016
Θέματα:
Pharmacology
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039228/
https://ncbi.nlm.nih.gov/pubmed/27733828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00305
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια